Daymark Health Raises $20M Series A to Scale Cancer Care Nationally

Daymark Health is announcing a $20 million Series A funding round, led by Healthier Capital — the firm founded by former One Medical CEO Amir Dan Rubin — and Blue Venture Fund, the collaborative investment vehicle representing 36 Blue Cross Blue Shield companies. Existing investors Maverick Ventures, Yosemite, and Oncology Ventures also participated, bringing Daymark's total funding to $31.5 million.

The raise comes just five months after Daymark's public launch — a milestone that reflects growing momentum and urgent demand for a better model of cancer care.

Daymark co-founder and CEO Dr. Justin Bekelman sees the moment as an inflection point for the industry: "We are seeing a tipping point in oncology, where payers feel the ongoing pressures of managing specialty risk and providers are seeking solutions that put patients first."

Lead investors echoed that conviction. "Daymark is breaking down the silos in healthcare delivery to better enable personalized care for patients with cancer, while improving outcomes and reducing avoidable costs," said Aman Mahajan, MD, PhD, Partner at Healthier Capital. "Daymark is delivering a transformational model of personalized, high-quality, value-based cancer care."

Blue Venture Fund's Kelsey Maguire emphasized the shared mission driving the partnership: "Daymark and Blue Venture Fund are passionate about a shared purpose — to give all patients the best possible care experience, driving better health outcomes and ensuring they feel seen, heard, and valued. We're thrilled to partner with Daymark as they redefine the cancer care experience and evolve what's possible in value-based oncology."

Read the full announcement to learn what this investment means for patients and the future of oncology.